Three years into a manufacturing collaboration, Germany’s Merck KGaA and South Korea’s Samsung BioLogics have decided to deepen their relationship even as Samsung reported an operating profit for the first time. More: Samsung reports operating profit, extends collaboration with Merck
read moreRBC Capital Markets analyst Randall Stanicky has fielded some investor pushback to his suggestion that Allergan could be a good breakup candidate. And Monday, he outlined his responses to the skeptics. More: Analyst backing an Allergan breakup is undeterred by
read morePfizer, which is struggling to build traction for its Remicade biosimilar in the U.S., has some new data it hopes can make a difference in building sales for its Inflectra. More: Can Pfizer's new Crohn's data help Inflectra pry away
read moreMerck & Co. surprised investors and analysts Friday with news that it had pulled its European application for a new Keytruda combo in non-small cell lung cancer. They haven’t taken it well. More: Keytruda sales forecasts take a hit after
read moreShire intends to take some manufacturing of its rare disease drug Cinryze in house after problems with a contractor led to a shortage of the drug. The move comes even as Shire has targeted three more plants for elimination in
read moreMSD has pulled back its application to market Keytruda (pembrolizumab) in the European Union in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC). More: MSD pulls EU filing for Keytruda combo
read more© 1994 - 2026 B.M. Pharmaceuticals